急性冠脉综合征后长期心血管与非心血管死亡的竞争风险分析
基于中国心血管协会数据库—胸痛中心登记的 156 万余例出院急性冠脉综合征患者,通过全国死因监测系统进行死亡原因链接,采用竞争风险框架分析心血管与非心血管死亡的累积发生率及时间演变。结果显示出院后 1 个月内心血管死亡是主要死因,12 个月后非心血管死亡相对增速更高,恶性肿瘤成为晚期死亡的首要原因。研究提示 ACS 后管理需从传统二级预防转向涵盖竞争风险的综合生存照护。
要点
- ACS 出院后 1 个月内心血管死亡是主要死因,12 个月后非心血管死亡相对增速更高。
- 年龄≥65 岁、慢性肾脏病和慢性心力衰竭是死亡的主要预测因素。
- 降脂治疗与全因死亡、心血管死亡和非心血管死亡风险降低均相关。
核心结论
- ACS 后死亡原因随时间从心血管原因向非心血管原因转变,恶性肿瘤成为晚期死亡的首要原因。
- ACS 后管理需要超越传统二级预防,转向涵盖全部竞争风险的综合生存照护。
研究设计与样本
- 多中心队列研究,纳入 2018 年 1 月至 2021 年 12 月出院诊断为 ACS 的 18 岁及以上患者 1562956 例。
- 数据来源于中国心血管协会数据库—胸痛中心,通过中国疾控中心死因报告系统进行全国死亡监测链接。
- 采用竞争风险框架分析心血管与非心血管死亡,并进行 12 个月界标分析和亚组分析。
主要发现
- 1562956 例患者中男性 1074289 例(68.7%),平均年龄 63.8±12.3 岁。
- 出院后 1 个月心血管死亡累积发生率为 1.24%,非心血管死亡为 0.26%。
- 12 个月后非心血管死亡相对增速高于心血管死亡。
- 缺血性心脏病占心血管死亡的 68.5%,恶性肿瘤占非心血管死亡的 38.3%,慢性肺病占非心血管死亡的 15.8%。
关键数值与推荐
- 年龄≥65 岁的亚分布风险比(sHR)为 3.78,95%CI:3.72-3.849。
- 慢性肾脏病的 sHR 为 2.07,95%CI:2.03-2.11。
- 慢性心力衰竭的 sHR 为 1.99,95%CI:1.96-2.02。
- 降脂治疗与全因死亡、心血管死亡和非心血管死亡风险降低均相关。
临床怎么用
- ACS 出院后早期应重点防范心血管死亡,远期需关注恶性肿瘤和慢性肺病等非心血管死亡风险。
- 对年龄≥65 岁、合并慢性肾脏病或慢性心力衰竭的患者应加强个体化风险评估与综合管理。
- 对 ACS 后患者应重视降脂治疗的持续应用,并推动肿瘤筛查和慢性肺病管理等综合生存照护措施。
局限性
- 原文未报告研究局限性的具体内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term mortality rates among postdischarge acute coronary syndrome (ACS) patients remain substantial. The temporal evolution and cause-specific drivers of this residual risk remain incomplete. OBJECTIVES: This study aimed to comprehensively investigate the cumulative incidence of cardiovascular (CV) and non-CV mortality after ACS discharge using a competing-risks framework. METHODS: In this multicenter cohort study, we analyzed data from the China Cardiovascular Association Database-Chest Pain Center. Mortality outcomes were ascertained through linkage with the Chinese Center for Disease Control and Prevention Cause of Death Reporting System via national mortality surveillance. Eligible patients were aged 18 years or older with a discharge diagnosis of ACS between January 2018 and December 2021. The primary outcome was all-cause mortality. Causes of death were categorized as CV or non-CV, which were analyzed as competing events. Cumulative incidence and landmark analysis at 12 months were conducted to evaluate temporal mortality patterns. Multivariate competing risks regression (Fine and Gray model) was used to identify predictors associated with the cause-specific mortality. Subgroup analyses were conducted across age, sex, and ACS subtypes. RESULTS: Of 1,562,956 eligible patients, 1,074,289 (68.7%) were men, and the mean age was 63.8 ± 12.3 years. The competing risks analysis revealed that CV death was the primary driver of mortality at 1-month discharge (1.24% vs 0.26% for non-CV); yet, non-CV mortality showed a higher relative growth than CV mortality after 12-month discharge. Ischemic heart disease (68.5%) was the predominant CV death, whereas non-CV death was dominated by malignancy (38.3%) and chronic pulmonary disease (15.8%). Age ≥65 years (subdistribution HR [sHR]: 3.78; 95% CI: 3.72-3.849), chronic kidney disease (sHR: 2.07; 95% CI: 2.03-2.11), and chronic heart failure (sHR: 1.99; 95% CI: 1.96-2.02) were leading predictors of death. Lipid-lowering therapy was associated with lower risks of all-cause, CV, and non-CV death. CONCLUSIONS: This national study demonstrates a transition in post-ACS mortality from CV to non-CV causes over time, with malignancy emerging as the leading cause of late-term death. These findings necessitate moving beyond traditional secondary prevention toward integrated survivorship care that addresses the full spectrum of competing risks.
引用
- Yang, Yin, Li, et al. Long-Term Cardiovascular and Noncardiovascular Mortality After Acute Coronary Syndrome: A Nationwide Competing-Risks Analysis of 1.56 Million Patients. J Am Coll Cardiol. 2026. PMID: 41706064. doi:10.1016/j.jacc.2025.12.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。